GH Research (GHRS) Projected to Release Earnings on Thursday

GH Research (NASDAQ:GHRS) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect GH Research to post earnings of ($0.3040) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 26, 2026 at 12:30 PM ET.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, analysts expect GH Research to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

GH Research Trading Up 0.4%

NASDAQ GHRS opened at $28.19 on Tuesday. GH Research has a 12-month low of $11.32 and a 12-month high of $31.00. The company has a fifty day simple moving average of $25.15 and a two-hundred day simple moving average of $19.82. The stock has a market cap of $1.93 billion, a P/E ratio of -30.64 and a beta of 1.29.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wells Fargo & Company assumed coverage on GH Research in a research report on Monday, July 27th. They issued an “overweight” rating and a $44.00 target price on the stock. Cantor Fitzgerald lifted their price target on GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. HC Wainwright dropped their price target on GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Citizens Jmp cut their price objective on GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, May 15th. Finally, Citigroup restated an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. Ten investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, GH Research currently has a consensus rating of “Moderate Buy” and an average target price of $40.78.

Institutional Trading of GH Research

A number of hedge funds and other institutional investors have recently made changes to their positions in GHRS. JPMorgan Chase & Co. acquired a new position in GH Research during the second quarter valued at $79,000. BNP Paribas Financial Markets grew its position in GH Research by 165.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after purchasing an additional 10,600 shares during the period. Osaic Holdings Inc. grew its position in GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the period. UBS Group AG raised its stake in shares of GH Research by 11.5% during the 3rd quarter. UBS Group AG now owns 511,464 shares of the company’s stock valued at $7,314,000 after buying an additional 52,882 shares during the last quarter. Finally, Lynx1 Capital Management LP raised its stake in shares of GH Research by 27.5% during the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock valued at $122,997,000 after buying an additional 1,854,238 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.